Search Results
Results found for "Sosei Heptares"
Posts (48)
- California gold rush for Sosei Heptares
November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative
- Verily links up with Sosei Heptares for GPCR drug discovery
Among those hitching their wagons to that star are Verily and Sosei Heptares, which have struck a research The financial details of the strategic collaboration weren’t released, but Sosei Heptares’ past two team-ups
- Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
December 2021 "Tokyo, Japan and Cambridge, UK, 24 December 2021 – Sosei Group Corporation (“Sosei Heptares under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million, with the amount to be recognized as revenue in the fourth
Other Pages (3)
- Annabelle Milner | Dr. GPCR Ecosystem
Alastair Brown (Sosei Heptares), where she is currently a final year Ph.D. student.
- Dr. Fiona Marshall | Dr. GPCR Ecosystem
As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Chris Langmead | Dr. GPCR Ecosystem
Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).
